Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Novartis to Build $700 Million Plant in Singapore

publication date: Nov 2, 2007
Novartis will construct a $700 million biotech manufacturing facility in the Singapore’s Tuas Biomedical Park. The plant will contain Novartis’ seventh – and largest – bioreactor worldwide. Once open, the new facility will employ 300 people. Construction will begin next year, with completion (and certification) expected in 2012. The facility will provide both clinical and commercial supplies of new biopharma drugs, which are increasingly important to Novartis.  More details...

Stock Symbol: (NYSE: NVS)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here